Plasma viremia decreases coincident with the appearance of virus-specific CD8+ T cells during acute HIV or SIV infection. This finding, along with demonstrations of viral mutational escape from CD8+ T cell responses and transient increase in plasma viremia after depletion of CD8+ T cells in SIV-infected monkeys strongly suggest a role for CD8+ T cells in controlling HIV/SIV. However, direct quantitative or qualitative correlates between CD8+ T cell activity and virus control have not been established. To directly assess the impact of large numbers of virus-specific CD8+ T cells present at time of SIV infection, we transferred in vitro expanded autologous central and effector memory-derived Gag CM9-, Nef YY9-, and Vif WY8-specific CD8+ T cell clones to acutely infected rhesus macaques. The cells persisted in PBMCs between 4 and 9 d, but were not detected in gut-associated lymphoid tissue or lymph nodes. Interestingly, a high frequency of the infused cells localized to the lungs, where they persisted at high frequency for >6 wk. Although persisting cells in the lungs were Ag reactive, there was no measurable effect on virus load. Sequencing of virus from the animal receiving Nef YY9-specific CD8+ T cells demonstrated an escape mutation in this epitope <3 wk postinfection, consistent with immune selection pressure by the infused cells. These studies establish methods for adoptive transfer of autologous SIV-specific CD8+ T cells for evaluating immune control during acute infection and demonstrate that infused cells retain function and persist for at least 2 mo in specific tissues.

Despite more than 2 decades of intensive research, an efficacious vaccine against HIV and AIDS is lacking. Passive immunization using HIV-neutralizing Abs can provide sterilizing immunity against pathogenic HIV/SIV hybrid viruses in nonhuman primate (NHP) models (13). However, vaccine induction of broadly cross-reactive neutralizing Ab responses that will likely be necessary for protection remains elusive, leading to an intense complementary research effort focusing on vaccines that can maximize the potential of adaptive cellular immunity (47).

Multiple indirect lines of evidence suggest that HIV and SIV virus replication can be partially controlled by CD8+ T cell responses: 1) the temporal correlation between CD8+ T cell expansion and reduced viremia during acute infection (810); 2) mutations leading to escape in defined viral CD8+ T cell epitopes (1114); 3) CD8+ cell depletion studies giving rise to increased viremia (1517); as well as 4) partial viral control after vaccine induction of CD8+ T cell responses in the absence of neutralizing Ab, under certain experimental conditions (49, 1821). However, no consistent cellular immune correlate with viral control has been demonstrated in HIV-infected patients or SIV-infected macaques asserting long-term control of viral replication (i.e., long-term nonprogressors, reviewed in Ref. 22). Also, a recent clinical trial aimed at generating HIV-reactive T cell responses failed to induce measurable protection against infection or reduce viral load after infection (23). The failure of current CD8+ T cell-based vaccines in HIV- and SIV-induced disease could be due to a quantitative defect (i.e., current vaccine protocols fail to generate a strong enough CD8+ T cell response). Alternatively, the vaccines might not induce a qualitatively appropriate response with a phenotype suitable for viral control or a combination of the two.

Adoptive transfer of Ag-specific T cells using syngeneic cells from inbred mice has helped to define effector mechanisms for immune-based tumor suppression (reviewed in Ref. 24), as well as protection against some viral infections (25, 26). The achievements using murine models led to clinical protocols where patient CD8+ T cells specific for tumor-associated Ags or virus are generated and expanded in vitro to large numbers and then adoptively transferred to the autologous host. Notwithstanding problems with in vivo persistence of infused T cells, positive clinical effects have been reported using T cells against different malignancies (2730) and viral infections (31). Therefore, it has been suggested that adoptive transfer of SIV-specific CD8+ T cells could be an important tool for determining what phenotype is critical for effective SIV suppression in vivo (32, 33). One impediment to these types of studies is the difficulty in generation/isolation, long-term maintenance, and large-scale expansion of virus-specific macaque T cell clones in vitro. A study by Berger et al. (34) in Macaca nemestrina using CMV as a model viral infection made strides toward establishing such methods, with adoptive transfers of Ag-specific CD8+ T cells. Building on this protocol, we have developed methods to efficiently generate, maintain and expand SIV-specific CD8+ T cell clones from SIV-infected rhesus macaques (35).

It has been suggested that current vaccines against SIV/HIV fail because by the time the memory CD8+ T cell responses expand after the viral challenge, usually 2–3 wk postinfection (PI) (36), the virus has gained an upper hand during this crucial delay, and the immune system cannot catch up: a model described as the “too little too late” hypothesis (37). In this study, we investigated whether large numbers of SIV-specific CD8+ T cells can impact the acute course of infection. To this end, we generated and characterized central and effector memory-derived CD8+ T cell clones from SIV DNA-vaccinated rhesus macaques specific for epitopes within the SIV proteins Gag, Nef, and Vif and performed autologous adoptive transfers after large-scale expansion. The hosts were i.v. challenged with high-dose SIVmac239 3 d before the CD8+ T cell adoptive transfers. The impact of the transferred cells was monitored by tracking their distribution and persistence, measuring the viral load, and assessing disease progression.

SIV-specific CD8+ T cells were generated from PBMCs isolated from two uninfected Indian rhesus macaques, M. mulatta (DBN2; Mamu A*01+/A*02+ and AZ15; Mamu A*02+) 2 mo after a third immunization using electroporation and SIV DNA vaccine constructs. The DNA vaccine contructs consisted of full-length SIVmac239 Gag, Pol, Vif, Tat, and Nef sequences as previously described (38, 63) (V. Patel, A. Valentin, V. Kulkarni, M. Rosati, C. Bergamaschi, R. Jalah, C. Alicea, J. T. Minang, M. T. Trivett, C. Ohlen, J. Zhao, M. Robert-Guroff, A. S. Khan, R. Draghia-Akli, B. K. Felber, and G. N. Pavlakis, submitted for publication) and an optimized rhesus IL-12 expression plasmid as adjuvant (R. Jalah, B. Ganneru, A. Valentin, V. Kulkarni, M. Rosati, C. Bergamaschi, G. Zhang, C. Alicea, G. N. Pavlakis, and B. K. Felber, manuscript in preparation). CD8+ T cell clones against the SIV Gag181–189CM9 epitope (CM9) or pools of 15-mer overlapping peptides spanning SIV Gag and the accessory proteins Nef, Vif, and regulatory protein Tat (Acc) were generated from PBMCs from DBN2 and against the Gag and Acc peptide pools for AZ15, as described previously (39). Briefly, isolated PBMCs were sorted into CD8+ central and effector memory T cells based on CD28, CD95, and CCR7 expression (central memory T cell [TCM]: CD28+CD95+CCR7+; effector memory T cell [TEM]: CD28CD95+CCR7; further details in Cell sorting and flow cytometry) (Fig. 1). The sorted TCM and TEM cell fractions were stimulated for 1 wk with irradiated autologous PBMCs pulsed with CM9 peptide (1 μg/ml; SynPep, Dublin, CA) (40), SIV Gag or Acc peptide pools (1 μg/ml; National Institutes of Health [NIH] AIDS Research and Reference Reagent Program, Germantown, MD) and the cells restimulated weekly with peptide-pulsed, irradiated autologous PBMCs in the presence of recombinant human IL-2 (50 IU/ml; NIH AIDS Research and Reference Reagent Program). Following two rounds of peptide stimulation, the virus-specific CD8+ T cells were cloned by limiting dilution and maintained essentially as described in Riddell et al. (41) and Berger et al. (42) using biweekly stimulation with anti-CD3 mAb (30 ng/ml; clone SP34-2; BD Biosciences, San Jose, CA) and irradiated human PBMCs and human EBV-transformed B cell lines (TM B-LCL; kindly provided by Drs. S.R. Riddell and P. D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, WA) as feeder cells, but without anti-CD28 mAb stimulation. APC and feeder cells were irradiated in a Mark I [137Cs] γ-irradiator (Shepherd & Associates, San Fernando, CA) at 6,000 and 12,500 rad for PBMCs and TM B-LCLs, respectively. Positive wells were tested for Ag specificity by flow cytometry using intracellular cytokine staining (ICS) for IFN-γ production and, in the case of SIV Gag CM9-specific CD8+ T cells, by staining with a CM9 peptide MHC class I/tetramer (Beckman Coulter, Miami, FL). SIV nonspecific autologous CD4+ T cell clones were generated from PBMCs from DBN2 and AZ15 as described (39). Animal care was according to the guidelines of the Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council, and the Health and Human Services guidelines “Guide for the Care and Use of Laboratory Animals” (National Research Council, 1996, National Academy Press, Washington, D.C.), under an Institutional Animal Care and Use Committee–approved protocol.

FIGURE 1.

Gating strategy and flow cytometry sorting analysis of TCM and TEM CD8+ T cell populations from a rhesus macaque (DBN2) immunized with a DNA vaccine construct containing full-length SIVmac239 Gag, Pol, Vif, Tat, and Nef sequences. CD8+ lymphocytes were singlet gated and defined as memory cells based on surface expression of CD95. TCM and TEM fractions were further defined and sorted based on CD28 and CCR7 expression.

FIGURE 1.

Gating strategy and flow cytometry sorting analysis of TCM and TEM CD8+ T cell populations from a rhesus macaque (DBN2) immunized with a DNA vaccine construct containing full-length SIVmac239 Gag, Pol, Vif, Tat, and Nef sequences. CD8+ lymphocytes were singlet gated and defined as memory cells based on surface expression of CD95. TCM and TEM fractions were further defined and sorted based on CD28 and CCR7 expression.

Close modal

Whole PBMCs were stained with fluorochrome-conjugated mAbs (all mAbs from BD Biosciences unless otherwise indicated) to CD4 (clone L200), CD8 (clone SK1), CD14 (clone MφP9), CD20 (clone 2H7), CD28 (clone CD28.2; Beckman Coulter), CD62L (clone SK11), CCR7 (clone 150503; R&D Systems, Minneapolis, MN), and CD95 (clone DX2). The CD8+ T cell fractions were then sorted into TCM (CD28+CD95+CCR7+) and TEM (CD28CD95+CCR7) by flow cytometry using a BD FACS Aria (BD Biosciences) prior to SIV peptide stimulation and cloning (Fig. 1). TEM clones were further sorted for the CD8+ T cell degranulation marker CD107a after SIV peptide stimulation using fluorochrome-conjugated CD107a mAb (clone H4A3).

CD8+ T cell epitopes were mapped by stimulation for 18–24 h with pools of 15-mer overlapping peptides spanning the entire SIV Gag and Acc peptide sequences in a peptide matrix IFN-γ ELISpot as described (43). Assays were repeated with each individual 15-mer or derivative 9-mer, for SIV Gag CM9 and Nef159–167YY9 (YY9) (44), or 8-mer, for SIV Vif97–104WY8 (WY8) (44, 45), peptide to confirm the epitope specificity.

In vitro reactivity of the virus-specific TCM- and TEM-derived CD8+ T cell clones was assessed by measuring intracellular IFN-γ and surface CD107a expression following stimulation with autologous PBMCs pulsed with SIV Gag CM9, Nef YY9, and Vif WY8 peptides or the relevant Gag or Acc peptide pools and SIVmac239-infected autologous CD4+ T cells. Briefly, CD8+ T cell clones were cocultured with PBMCs that were prepulsed for 1 h with the appropriate peptide or peptide pool (1 μg/ml) or with virus-infected autologous CD4+ T cells as described (35); a CD8+:CD4+ T cell ratio of 1:1 was used in 0.5 ml suspension of 1 × 106 cells total in 5-ml polypropylene tubes. Nonpulsed autologous PBMCs or uninfected autologous CD4+ T cells were included as negative control APC. PE-conjugated anti-human CD107a mAb was added to the cell suspensions before incubation. Monensin, 20 μl/test of a 1:20 dilution (Golgi stop; BD Biosciences) was added after 1 h of incubation and the cells incubated for additional 4 h. Cells were washed and surface and intracellular stained with PerCP-Cy5.5 conjugated anti-human CD8 mAb and FITC-conjugated anti-human IFN-γ mAb (clone 4S.B3), respectively. Samples were acquired on a BD FACSCalibur flow cytometer (BD Biosciences) and data analyses performed using FCS Express Version 3 (De Novo Software, Los Angeles, CA). Dead cells were excluded from the analyses based on forward versus side-scatter gating and at least 100,000 live cell events collected for each sample.

Virus-specific CD8+ T cell clones with confirmed in vitro reactivity to cognate peptide-pulsed or SIV-infected autologous CD4+ T cells were analyzed for surface expression of chemokine receptors/homing markers as well as PD-1 using the following mAbs (all mAbs were from BD Biosciences, unless otherwise indicated): CCR5 (clone 3A9), CCR7 (clone 150503), CCR8 (clone 191704, R&D Systems), CCR9 (clone 112509.111, R&D Systems), CD103 (clone 2G5), α4β7 (clone ACT1), and PD-1 (R&D Systems, catalog number BAF1086). An anti-human CD45 mAb (clone HI30) that does not cross-react with rhesus macaque cells was included to exclude human feeder cells. Sample acquisition and analyses were as described in Bolton et al. (62).

Virus stocks for infection of CD4+ T cells used as APC in in vitro assays were produced by transfection of HEK293T cells with SIVmac239 using TransIt-293 reagent (Mirus Corporation, Madison, WI) as described (46). CD4+ T cells were infected by incubating with aliquots of virus stock for 2 to 3 h using the Viromag magnetofection reagents (Oz Biosciences, Marseille, France); a ratio of 7.5 μl of beads/ml of clarified transfection supernatant was used as recommended by the manufacturer (Oz Biosciences). Virus stocks with ∼1 × 109 viral RNA copies Eq/ml in a volume of 250 μl were added per 1 × 106 CD4+ T cells. Virus exposed CD4+ T cells were cultured for 7 d, with IL-2 addition every 2 to 3 d at a final concentration of 50 IU/ml prior to use as APC to ensure optimal numbers of SIV-infected cells (35).

A stock of SIVmac239 with an in vivo titer of 3.2 × 105 AID50/ml was used for animal infections. This virus stock was a kind gift from Dr. Ronald C. Desrosiers of the New England Regional Primate Research Center, Harvard Medical School, Southborough, MA (17). All three monkeys were infected 7 mo after the third DNA vaccine administration i.v. (via the saphenous vein) and 3 d prior to CD8+ T cell infusion using a dose of 100 AID50.

Two Gag CM9- and Vif WY8-specific CD8+ T cell clones (one clone of each specificity TCM- and the other TEM-derived) from DBN2 as well as one Vif WY8-specific TCM-derived and two Nef YY9-specific TEM-derived CD8+ T cell clones from AZ15 were selected for expansion and adoptive transfer. CD8+ T cell clones were selected based on in vitro reactivity (IFN-γ, CD107a) to autologous peptide-pulsed PBMCs and virus-infected CD4+ T cells. The CD8+ T cell clones of interest were expanded in vitro for 6–8 wk through repeated cycles of biweekly stimulation with anti-CD3 mAb (BD Biosciences) and irradiated human PBMCs and human TM B-LCLs as feeder cells to obtain billions of cells of each clone as described (35, 39). To track the tissue distribution and in vivo persistence of infused cells, half of each clonal population was stained with a fluorescent dye, TCM and TEM labeled with PKH26 (red dye; Sigma-Aldrich, St. Louis, MO) and CFSE (green dye; Invitrogen, Carlsbad, CA), respectively, and then pooled with their unlabeled counterparts.

TCM and TEM clones from each animal were combined, washed extensively, resuspended in 50 ml saline solution supplemented with 2% autologous serum, and infused (1.5 ml/min) i.v. to the autologous animal. AZ15 and DBN2 were infused with ∼4 and ∼12 billion CD8+ T cells total, respectively. The animals were administered low dose (104 U/kg/d) IL-2 daily for 10 d to support infused T cell survival and proliferation (24), as was the control. Blood was collected from all three monkeys before and 30 min postinfusion for the two monkeys that received cells and then from all three monkeys every other day during the first week postinfusion and once a week thereafter. Bronchoalveolar lavage (BAL), GALT, and lymph node (LN) samples were also collected from all three animals 2 and 9 d postinfusion (i.e., days 5 and 12 postchallenge) and BAL once a week thereafter. Blood, BAL, GALT, and LN biopsies were collected 3 wk prior to virus challenge and 6 mo after receiving the third DNA vaccine immunization to determine the baseline (memory vaccine-induced) CD8+ T cell responses to SIV Gag and Acc peptide. CD4+ T cell counts were monitored using BD Tru Count absolute cell counting tubes (BD Biosciences), according to the manufacturer’s recommendations.

Cell-associated viral DNA was extracted from PBMC, BAL, LN, and GALT samples using the Qiagen DNA Mini Kit as recommended by the manufacturer (Qiagen, Valencia, CA). The copy numbers of SIV DNA (gag-specific target) and of the macaque CCR5 gene, for cell equivalents, were codetermined in a duplex format quantitative PCR (qPCR). The assay was as described in Cline et al. (47) with omission of the reverse transcription step and with the addition of primers and probe (100 nM final concentration each) specific for the macaque CCR5 sequence and use of the plasmid pR1-D of the M. mulatta CCR5 gene promoter region (48) as a quantitation standard (Genbank Accession No. AF252567; www.ncbi.nlm.nih.gov/nuccore/9488623?report=genbank; this was a kind donation of Dr. Sunil K. Ahuja of the University of Texas Health Science Center, San Antonio, TX). The duplex qPCR assay was run on an MX3000P instrument (Stratagene, La Jolla, CA), and results are reported as nominal SIV gag DNA copy numbers per 100,000 cell equivalents determined by copy numbers of the CCR5 sequence and based on two nominal copies of CCR5 per rhesus macaque cell (M. Piatak, unpublished observations).

Viral RNA was extracted from plasma, BAL, LN, and GALT samples essentially as described previously (47). Viral replication was quantified using a FRET probe-based real-time RT-PCR (TaqMan, Applied Biosystems, Foster City, CA) assay described previously (17, 47). All RT-PCR reactions were run on ABI Prism 7700 Sequence Detection System, and the fluorescent signal-based quantitation of viral RNA copy numbers in test samples were determined by ABI sequence detection software (Applied Biosystems).

SIVmac239 regions encoding Gag CM9, Nef YY9, Tat28–35SL8 (SL8), and Vif WY8 were sequenced as described (47). Briefly, cell-free plasma was obtained by centrifugation of EDTA anticoagulated whole blood on a Ficoll density gradient and viral RNA extracted for use in RT-PCR as previously reported (47). RT was performed by using SuperScript first strand synthesis system for RT-PCR (Invitrogen). PCR reactions were carried out in 50 μl volumes; the PCR buffer contained 200 μM dNTP, 300 nM of each primer, 1.5 mM MgCl2, and 1.0 unit of platinum Taq polymerase. The PCR conditions were 94°C for 2 min followed by 45 cycles of 94°C for 30 s, 52°C for 30 s and 72°C for 30 s. The primers for each epitope were: CM9 pair: 5′-ATGCCAAAACAAGTAGACCA-3′ and 5′-GATCCTGACGGCTCCCTAAG-3′; YY9 pair: 5′-GAGGCCAAAAGTTCCCCTAA-3′ and 5′-TCTTGCGGTTAGCCTTCTTC-3′; SL8 pair: 5′-AACCATGGGATGAATGGGTA-3′ and 5′-GCCTTAGCCTTTTTCGGAGT-3′; and WY8 pair: 5′-GTTTGCTATGTGCCCCATTT-3′ and 5′-TGTTTCCAGGTGGGATTCTC-3′. Both strands of each amplicon were directly sequenced, and nucleotide sequences were aligned pairwise to the GenBank SIVmac239 sequence (Accession no. M33262.1; www.ncbi.nlm.nih.gov/nuccore/334647?report=Summary) (49). Nucleotide changes in and around the region encoding the epitope resulting in amino acid replacements as well as silent mutations were noted.

Attempts by our group to in vitro prime SIV-specific CD8+ T cell clones from naive rhesus macaques for use in autologous adoptive transfer studies using autologous peripheral blood monocyte-derived dendritic cells pulsed with viral peptides failed to generate clones of sufficient functional avidity to react to SIV-infected cells in vitro (data not shown). To facilitate efficient priming, we therefore chose to prime a cohort of rhesus macaques by DNA vaccination using electroporation of a mixture of optimized plasmids expressing the SIVmac239 proteins Gag, Pol, Nef, Tat, and Vif and an optimized rhesus IL-12 expression plasmid as adjuvant. All vaccinated monkeys mounted robust cellular and humoral responses to the relevant SIV Ags after three rounds of vaccination; the detailed analyses of the vaccine-induced responses are being reported elsewhere (V. Patel et al., submitted for publication). Virus-specific CD8+ T cell clones were generated from two of the DNA-vaccinated animals (DBN2, Mamu A*01+/A*02+; AZ15, Mamu A*02+) 2 mo after the third DNA immunization. A third vaccinated monkey (DBK1, Mamu A*01+) was used as a control for vaccine-induced antiviral effect. Given a recent report by Berger et al. (34) showing enhanced survival/persistence of TCM- compared with TEM-derived CMV-specific CD8+ T cell clones in vivo, we sorted CD8+ T cells from PBMCs from DBN2 and AZ15 into TCM and TEM based on CD28, CD95, and CCR7 expression (TCM: CD28+CD95+CCR7+ and TEM: CD28CD95+CCR7) (Fig. 1) prior to stimulation with SIV peptides or peptide pools and limiting dilution cloning (35, 39). We reasoned that targeting multiple epitopes from more than one SIV protein would provide a better chance for infused virus-specific CD8+ T cells to have an impact on virus replication in infected monkeys. We therefore isolated multiple CD8+ T cell clones specific for the Mamu A*01-restricted SIV Gag CM9 epitope and the Mamu A*02-restricted SIV Nef YY9 and Vif WY8 epitopes for their ability to produce IFN-γ and the CD8+ T cell degranulation marker CD107a upon peptide stimulation, as well as to proliferate robustly (data not shown). The clones were analyzed for intracellular IFN-γ and surface CD107a expression by flow cytometry following stimulation with SIV peptide-pulsed autologous PBMC and SIV-infected autologous CD4+ T cell clones.

From these analyses, we selected a series of clones from the two macaques for infusion (Table I). These TCM and TEM clones showed robust IFN-γ (Fig. 2A) and CD107a responses (data not shown) to peptide-pulsed APCs and to autologous SIV-infected CD4+ T cells (Fig. 2B), a more biologically relevant stimulus. Regardless of TCM or TEM origin, all clones had obtained an effector memory phenotype (CD8+CD28CD95+CCR7) after in vitro culture (Fig. 2C; data not shown), consistent with previous observations by Berger et al. (34) for CMV-specific clones from M. nemestrina. Comprehensive analyses of the CD8+ T cell clones selected for adoptive transfer for surface expression of chemokine receptors/homing markers and the marker of T cell exhaustion, PD-1, showed clonal differences in the pattern and levels of expression of these markers after in vitro expansion not related to their in vivo origin (i.e., TCM versus TEM). Overall, most of the clones were CCR5high but showed low to negative expression of CCR9, CCR7, and CCR8, whereas expression of the gut homing markers, α4β7 and CD103, or the exhaustion marker, PD-1, varied between the clones (Supplemental Fig. 1; example for one TCM- and one TEM-derived clone).

Table I.
CD8+ T cell specificities, MHC class I restriction, and number of cells infused
Monkey ID (Mamu)CD8+ T Cell Specificity (Origin)aMamu RestrictionNo. of Cells Infusedb
AZ15 (A*02) Nef-YY9-7 (TEMA*02 0.8 × 109 
Nef-YY9-12 (TEMA*02 1.4 × 109 
Vif-WY8-10 (TCMA*02 1.6 × 109 
DBN2 (A*01/*02) Gag-CM9-18c (TEMA*01 5.8 × 109 
Gag-CM9-19 (TCMA*01 2.6 × 109 
Vif-WY8-4 (TCMA*02 2.1 × 109 
Vif-WY8-39 (TEMA*02 1.6 × 109 
DBK1 (A*01) No CD8+ T cells NA NA 
Monkey ID (Mamu)CD8+ T Cell Specificity (Origin)aMamu RestrictionNo. of Cells Infusedb
AZ15 (A*02) Nef-YY9-7 (TEMA*02 0.8 × 109 
Nef-YY9-12 (TEMA*02 1.4 × 109 
Vif-WY8-10 (TCMA*02 1.6 × 109 
DBN2 (A*01/*02) Gag-CM9-18c (TEMA*01 5.8 × 109 
Gag-CM9-19 (TCMA*01 2.6 × 109 
Vif-WY8-4 (TCMA*02 2.1 × 109 
Vif-WY8-39 (TEMA*02 1.6 × 109 
DBK1 (A*01) No CD8+ T cells NA NA 
a

CD8+ T cells from AZ15 and DBN2 were sorted based on surface phenotype (TCM: CD28+CD95+CCR7+; TEM: CD28CD95+CCR7) before generation of SIV-specific lines, cloning, and characterization in vitro.

b

Total number of cells of each clone included in pool of cells infused i.v.; half of the cells from each clone were stained with either PKH26 (TCM) or CFSE (TEM).

NA, not applicable.

FIGURE 2.

TCM- and TEM-derived CD8+ T cell clones exhibit similar functional reactivity, and both display an effector memory surface phenotype after culture in vitro. TCM- and TEM-derived SIV-specific CD8+ T cell clones from two rhesus macaques, AZ15 and DBN2, were stimulated with PBMCs pulsed with the appropriate peptides (A) or autologous SIV-infected CD4+ T cell clones (B). IFN-γ expression by the TCM- and TEM-derived clones was measured by ICS and flow cytometry. The surface phenotype of TCM- and TEM-derived clones was determined using fluorochrome-conjugated mAbs to CD28 and CD95 followed by flow cytometric analyses (C).

FIGURE 2.

TCM- and TEM-derived CD8+ T cell clones exhibit similar functional reactivity, and both display an effector memory surface phenotype after culture in vitro. TCM- and TEM-derived SIV-specific CD8+ T cell clones from two rhesus macaques, AZ15 and DBN2, were stimulated with PBMCs pulsed with the appropriate peptides (A) or autologous SIV-infected CD4+ T cell clones (B). IFN-γ expression by the TCM- and TEM-derived clones was measured by ICS and flow cytometry. The surface phenotype of TCM- and TEM-derived clones was determined using fluorochrome-conjugated mAbs to CD28 and CD95 followed by flow cytometric analyses (C).

Close modal

Data from a parallel study with chronically infected rhesus macaques showed limited persistence of infused autologous virus-specific CD8+ T cells in PBMC (62). Thus, adoptive transfer at time of infection could result in clearance of infused cells before appreciable virus replication starts. To avoid this scenario and ensure that the maximum numbers of infused cells are present at time of a limited infection, the monkeys were infected i.v. with 100 AID50 of SIVmac239 virus 3 d before T cell adoptive transfer. Plasma viral loads were analyzed on day 3 PI (day of infusion) by highly sensitive qPCR, and all three animals showed low but detectable viremia (AZ15 = 180 RNA copies/ml; DBN2 = 1200 copies/ml; DBK1 = 200 copies/ml; limit of detection >30 RNA copies/ml).

SIV Gag CM9- and Vif WY8-specific clones (one TCM- and TEM-derived clone of each specificity) from DBN2 and two TEM-derived Nef YY9 and one TCM-derived Vif WY8-specific CD8+ T cell clones from AZ15 were expanded in vitro to obtain 0.8–6 × 109 cells of each clone (Table I). To track the different clones after transfer, half of the cells of each clonal population were stained with a fluorescent dye; TCM and TEM were labeled with PKH26 and CFSE, respectively. The cells were pooled and infused i.v. to the autologous animal. The animals received a low dose (104 U/kg/d) of IL-2 for 10 d postinfusion to support survival and proliferation. Because Picker et al. (50) have previously shown that increased CD4+ T cell activation following IL-15 treatment does not elevate plasma viremia in chronically infected rhesus macaques, we did not anticipate any effects of IL-2 on viral load. The treatment was well tolerated, and no adverse effects were observed.

To assess the immediate engraftment of infused cells, we analyzed the CD3+CD8+ fraction of the lymphocyte gate in the 30 min postinfusion blood samples for labeled cells (Fig. 3A). Taking into account that only half of the infused cells were labeled, ∼5.6% and ∼16% of the CD8+ fraction of PBMCs collected 30 min postinfusion from AZ15 and DBN2, respectively, were infused cells (Fig. 3B). The TCM-derived infused cells were ∼4% and ∼8% of the CD8+ T cell fraction in PBMCs from AZ15 and DBN2, respectively, and the corresponding numbers for TEM-derived cells were ∼1.4% and ∼8%. The higher overall frequencies of the infused CD8+ T cells seen 30 min postinfusion in PBMCs from DBN2 correlated with the 3-fold higher number of cells infused in this monkey compared with AZ15 (Table I). The frequency of labeled cells in PBMCs declined with a similar kinetics in both animals and although present at day 4, no labeled cells could be detected by day 9 postinfusion. The TCM-derived cells from AZ15 persisted better in PBMC than the TEM-derived clones, despite the ∼1.5-fold higher frequency of TEM- compared with TCM-derived cells in the initial pool of infused CD8+ T cells for this monkey. In contrast, the TEM-derived clones, which were ∼1.5-fold more frequent than the TCM-derived cells in the initial pool of infused cells, persisted better in DBN2. To determine homing to lymphoid and mucosal tissue, biopsies from LN and GALT samples were analyzed on days 2 and 9 postinfusion but no labeled cells could be detected in either tissue at any of these time points (Fig. 3C). Thus, the differences we observed in persistence of infused SIV-specific CD8+ T cell clones in PBMCs seemed to be clonal in nature and not related to their TCM or TEM origin.

FIGURE 3.

I.v. infused ex vivo expanded virus-specific TCM- and TEM-derived CD8+ T cell clones show similar distribution and persistence in vivo. Half of the clonal population of TCM- and TEM-derived virus-specific CD8+ T cell clones from two rhesus macaques, DBN2 and AZ15, were stained with PKH26 and CFSE, respectively, and the pool of stained and unstained cells adoptively transferred to the monkeys. The distribution and persistence of the infused cells was analyzed by flow cytometry by gating for the CD3+CD8+ T cell fraction of the “live gate” of the forward and side-scatter plot (A). PBMC (B), LN, and GALT (C) samples were analyzed at indicated time points postinfusion.

FIGURE 3.

I.v. infused ex vivo expanded virus-specific TCM- and TEM-derived CD8+ T cell clones show similar distribution and persistence in vivo. Half of the clonal population of TCM- and TEM-derived virus-specific CD8+ T cell clones from two rhesus macaques, DBN2 and AZ15, were stained with PKH26 and CFSE, respectively, and the pool of stained and unstained cells adoptively transferred to the monkeys. The distribution and persistence of the infused cells was analyzed by flow cytometry by gating for the CD3+CD8+ T cell fraction of the “live gate” of the forward and side-scatter plot (A). PBMC (B), LN, and GALT (C) samples were analyzed at indicated time points postinfusion.

Close modal

To assess the effect of the transferred virus-specific CD8+ T cells on virus replication in vivo, we measured viral RNA and DNA levels by qPCR in blood, LN, and GALT samples at different time points PI. Whereas one infused monkey had a slightly faster kinetics and higher peak plasma RNA compared with the control and second infused animal, similar levels of plasma viral RNA (Fig. 4A) and cell-associated viral DNA and RNA per 100,000 PBMCs (Fig. 4B) were observed for all three monkeys at ramp-up as well as set point. Similar to our findings in PBMCs, comparable levels of cell-associated viral DNA and RNA were observed in LN and GALT biopsies (Table II). At certain time points, viral load data from the control animal were elevated in either tissue compared with infused monkeys, but this was reversed at other time points. Thus, the infused virus-specific CD8+ T cells had no measurable effect on either the amount of plasma virus or the number of infected cells in PBMCs, LNs, or gut mucosa; the DNA vaccination, as used in the current study, did not appear to provide meaningful acute protective effect against high-dose i.v. challenge with SIVmac239.

FIGURE 4.

Adoptive transfer of ex vivo expanded virus-specific CD8+ T cell clones show no measurable effect on the virus load or the number of circulating CD4+ T cells in peripheral blood. Virus load in two animals infused with virus-specific CD8+ T cells, DBN2 and AZ15, as well as a control animal, DBK1, was determined on day 0, 3 (day of infusion), 4, 5, and 7 postchallenge and once a week thereafter by analyzing cell-free plasma viral RNA (A) or cell-associated viral DNA (B) levels by qPCR. The frequency of circulating CD4+ T cells in PBMCs was determined using the BD Tru Count kit (BD Biosciences) (C).

FIGURE 4.

Adoptive transfer of ex vivo expanded virus-specific CD8+ T cell clones show no measurable effect on the virus load or the number of circulating CD4+ T cells in peripheral blood. Virus load in two animals infused with virus-specific CD8+ T cells, DBN2 and AZ15, as well as a control animal, DBK1, was determined on day 0, 3 (day of infusion), 4, 5, and 7 postchallenge and once a week thereafter by analyzing cell-free plasma viral RNA (A) or cell-associated viral DNA (B) levels by qPCR. The frequency of circulating CD4+ T cells in PBMCs was determined using the BD Tru Count kit (BD Biosciences) (C).

Close modal
Table II.
Cell-associated viral DNA and RNA in LN and GALT biopsies
TissueNo. of d PIDNAa
RNAb
AZ15DBN2DBK1AZ15DBN2DBK1
GALT 12 1.8 × 104 1.8 × 103 1 × 103 1.9 × 106 5.6 × 104 2.2 × 104 
LN 9.3 × 101 3.4 × 101 8 × 100 5.4 × 103 1.5 × 103 7 × 101 
12 2.6 × 103 1.7 × 103 3.6 × 103 5.2 × 104 5.7 × 104 1.3 × 105 
TissueNo. of d PIDNAa
RNAb
AZ15DBN2DBK1AZ15DBN2DBK1
GALT 12 1.8 × 104 1.8 × 103 1 × 103 1.9 × 106 5.6 × 104 2.2 × 104 
LN 9.3 × 101 3.4 × 101 8 × 100 5.4 × 103 1.5 × 103 7 × 101 
12 2.6 × 103 1.7 × 103 3.6 × 103 5.2 × 104 5.7 × 104 1.3 × 105 
a

Cell-associated viral DNA copies per 100,000 cells.

b

Cell-associated viral RNA copies per 100,000 cells.

We next investigated if virus-specific CD8+ T cell infusion during the acute phase of infection would lead to better preservation of CD4+ T cells. There was a steady loss of CD4+ T cells during the first week postchallenge dipping to below 50% of prechallenge baseline counts for AZ15 and DBK1, or as low as 20% for DBN2, before rebounding to a set point of ∼60% of the frequency seen on the day of challenge (day 0) for all three monkeys (Fig. 4C). Thus, there was no measurable effect of the SIV-specific CD8+ T cell infusions on the CD4+ T cell counts.

BAL represents a conveniently sampled compartment for assessment of immune responses at a mucosal site, and it has been shown that lymphocytes present in the lungs share similarities with those present in the upper gastrointestinal tract (51). BAL samples were collected on day 2 postinfusion and once a week thereafter, and the frequency of CD3+CD8+PKH26+ (TCM) and CFSE+ (TEM) cells in the lungs of the monkeys was determined by flow cytometry.

After adjusting for labeling and assuming comparable survival and persistence of stained and unstained cells, the infused cells (PKH26+ and CFSE+) made up ∼50% and 84% of CD8+ T cells in BAL samples from AZ15 and DBN2, respectively, 48 h postinfusion (Fig. 5A). Strikingly, the infused cells persisted for a long period in the lungs with substantial frequencies observed >6 wk postinfusion (e.g., ∼14% of CD8+ T cells in BAL from DBN2 on day 45 postinfusion were infused cells) (Fig. 5A). Similar to our observation in PBMCs, the TCM-derived CD8+ T cell clones persisted in the lungs longer than the TEM-derived cells in AZ15, whereas the TEM-derived cells in DBN2 showed better persistence than TCM-derived cells.

FIGURE 5.

T cell persistence, function, and viral load in BAL samples. A, Virus-specific TCM- and TEM-derived CD8+ T cell clones from two rhesus macaques, DBN2 and AZ15, half of which were stained with PKH26 and CFSE, respectively, and were infused 3 d after challenge with SIVmac239. Infused cells were tracked using flow cytometry at indicated time points (B). Cell-free viral RNA and cell-associated viral DNA and RNA were determined at indicated time points by qPCR. DBN2 and AZ15 received virus-specific CD8+ T cells. Gray dashed lines show threshold of detection of cell-associated viral DNA and RNA (>10 copies/100,000 cells). C, Cells from BAL from DBN2 were stimulated with SIV Acc peptide pool or the SIV Gag CM9 peptide as indicated. The frequency of IFN-γ–expressing cells was determined by ICS and flow cytometry.

FIGURE 5.

T cell persistence, function, and viral load in BAL samples. A, Virus-specific TCM- and TEM-derived CD8+ T cell clones from two rhesus macaques, DBN2 and AZ15, half of which were stained with PKH26 and CFSE, respectively, and were infused 3 d after challenge with SIVmac239. Infused cells were tracked using flow cytometry at indicated time points (B). Cell-free viral RNA and cell-associated viral DNA and RNA were determined at indicated time points by qPCR. DBN2 and AZ15 received virus-specific CD8+ T cells. Gray dashed lines show threshold of detection of cell-associated viral DNA and RNA (>10 copies/100,000 cells). C, Cells from BAL from DBN2 were stimulated with SIV Acc peptide pool or the SIV Gag CM9 peptide as indicated. The frequency of IFN-γ–expressing cells was determined by ICS and flow cytometry.

Close modal

Because the infused virus-specific CD8+ T cells persisted for long periods in the lungs, we investigated if virus could be detected in BAL. BAL supernatant or cell pellets from BAL were used to measure cell-free viral RNA or cell-associated viral DNA and RNA by qPCR. We detected cell-free and cell-associated viral RNA and DNA in BAL from all three animals (Fig. 5B). Initially the levels were similar, but from 4 wk PI, the two Mamu A*01+ animals, DBN2 and DBK1, showed greater than one-log lower cell-free and cell-associated viral load than the Mamu A*01-negative monkey, AZ15. Our data thus indicate that even though the infused virus-specific CD8+ T cells persisted in the lungs, they did not have any measurable effect on virus load in this mucosal compartment.

Due to our finding of comparable virus load in the animals infused with virus-specific CD8+ T cells and the control monkey, we investigated whether the infused cells retained functional activities. Cells recovered from BAL samples collected 5 wk PI (day 32 postinfusion) in DBN2 were stimulated with the SIV Gag CM9 peptide or Acc peptide pool and the frequency of IFN-γ–producing cells determined by flow cytometry. Approximately 12% of BAL-derived CD8+ T cells from DBN2 (Mamu*A01+) responded to SIV Gag CM9 peptide stimulation. When BAL cells from DBN2 were gated based on PKH26 and CFSE staining, 2% and 61% of the PKH26+ (TCM) and CFSE+ (TEM) cells, respectively, responded to SIV Gag CM9 peptide (Fig. 5C). The corresponding numbers for SIV Acc peptide pool reactive CD8+ T cells in BAL samples from DBN2 were ∼18%, ∼17%, and ∼3.5%, respectively. As seen in Fig. 5A, few infused cells persisted in AZ15 at the time point for this analysis (day 32 postinfusion). However, despite the low frequency, 11% and 40% of the persisting PKH26+ (TCM) and CFSE+ (TEM) cells, respectively, in BAL from this monkey showed IFN-γ responses following stimulation with SIV Acc peptide pool (data not shown). Thus, infused CD8+ T cells persisting in the lungs retained Ag specificity and reactivity 32 d postinfusion.

To investigate the potential impact of the infused CD8+ T cells on the magnitude and kinetics of endogenous responses, we next analyzed the development of virus-induced CD8+ T cell responses in the animals. The frequencies of SIV Gag CM9 and Tat SL8 responding CD8+ T cells in PBMCs from the Mamu A*01+ animals, DBN2 (infused) and DBK1 (control), collected preinfection and at two different time points PI were determined by MHC class I/tetramer staining followed by flow cytometry (Fig. 6A). Overall, both animals had a similar expansion of endogenous CM9- and SL8-specific responses, with DBN2 having a somewhat lower response.

FIGURE 6.

Adoptive transfer of virus-specific CD8+ T cells does not significantly affect the endogenous SIV-specific T cell response. A, PBMCs collected at the indicated time points from the two Mamu A*01-positive monkeys, DBN2 and DBK1, were stained with SIV Tat SL8 or Gag CM9 tetramers and CD8 mAb. B, PBMCs from DBN2 and DBK1 collected pre- and postinfusion were stimulated with SIV Tat SL8, Gag CM9, and Acc peptide pool and the percentage of CD8+ IFN-γ–producing T cells determined by flow cytometry or the number of IFN-γ–producing cells determined by ELISpot (C). D, PBMCs from AZ15, DBN2, and DBK1 collected on day 39 postinfusion were stimulated with SIV Acc, Env, Gag, and Pol peptide pools and the number of Ag-induced IFN-γ–producing T cells determined by ELISpot.

FIGURE 6.

Adoptive transfer of virus-specific CD8+ T cells does not significantly affect the endogenous SIV-specific T cell response. A, PBMCs collected at the indicated time points from the two Mamu A*01-positive monkeys, DBN2 and DBK1, were stained with SIV Tat SL8 or Gag CM9 tetramers and CD8 mAb. B, PBMCs from DBN2 and DBK1 collected pre- and postinfusion were stimulated with SIV Tat SL8, Gag CM9, and Acc peptide pool and the percentage of CD8+ IFN-γ–producing T cells determined by flow cytometry or the number of IFN-γ–producing cells determined by ELISpot (C). D, PBMCs from AZ15, DBN2, and DBK1 collected on day 39 postinfusion were stimulated with SIV Acc, Env, Gag, and Pol peptide pools and the number of Ag-induced IFN-γ–producing T cells determined by ELISpot.

Close modal

A similar pattern was observed when we evaluated virus-specific T cell function by measuring the percentage of IFN-γ–producing CD8+ T cells in PBMCs following stimulation with SIV Gag CM9, Tat SL8, and Acc peptide pool by flow cytometry (Fig. 6B) or the number of IFN-γ–producing cells in PBMCs in response to these Ags by ELISpot (Fig. 6C). Thus, whereas the baseline levels of the endogenous vaccine-induced responses as well as the kinetics of development of virus-specific CD8+ T cell responses following challenge were similar for the infused animal DBN2 and the control animal DBK1, the CD8+ T cell responses postchallenge were somewhat higher in the control monkey. In line with the diminished endogenous responses in DBN2 compared with the control DBK1, we observed an escape mutation in the SIV Tat SL8 epitope between 3 and 8 wk PI in virus recovered from plasma from DBK1 but not from virus in DBN2 (data not shown). Because escape mutations are known to occur in this epitope very early during acute infection (36, 45), our finding may suggest a skewing of the early endogenous response, with a dampened Tat SL8 response in DBN2 following infusion of CD8+ T cells specific to other epitopes (Gag CM9 and Vif WY8) compared with the control animal DBK1. Our observation of slightly higher frequencies of SIV Tat SL8 MHC class I/tetramer positive (Fig. 6A) and SIV Tat SL8-reactive CD8+ T cells (Fig. 6B, 6C) in PBMCs from the control monkey, DBK1, compared with the test monkey, DBN2, further point to a possible dampening of the endogenous responses in DBN2, although the differences did not reach statistical significance given our small sample size.

We next investigated if the diversity of the endogenous virus-induced CD8+ T cell responses was affected by the adoptive transfer. PBMC samples from all three monkeys were collected on day 42 postchallenge (i.e., day 39 postinfusion for AZ15 and DBN2) and stimulated with peptide pools spanning the entire Gag, Pol, Env, and Acc SIV proteins and IFN-γ production measured by ELISpot. We could not detect consistent differences in SIV responses between infused animals AZ15 and DBN2 and the control DBK1 (Fig. 6D). The higher frequencies of SIV Gag peptide pool responding cells in PBMCs from DBN2 and DBK1 compared with AZ15 seem to be largely due to the robust SIV Gag CM9-specific responses seen in these Mamu A*01+ monkeys (Fig. 6A). Overall, a similar spectrum of virus-induced endogenous CD8+ T cell responses was observed in PBMCs from all three monkeys with a somewhat higher magnitude of SIV Acc- and Gag-induced endogenous responses seen in the control animal, DBK1.

Given the lack of a measurable effect of the infused CD8+ T cells on virus load in plasma or BAL, we investigated if amino acid changes had occurred in any of the targeted epitopes before the peak in endogenous virus-induced CD8+ T cell responses normally seen after 3 wk PI (36, 45). Regions spanning the CD8+ T cell epitopes, SIV Gag CM9, Nef YY9, and Vif WY8, were sequenced from virus extracted from plasma and analyzed for amino acid changes 1, 2, 3, 5, and 9 wk PI.

Sequencing of plasma virus from animal AZ15 revealed an A to T switch in the codon for the second amino acid of the Mamu A*02-restricted SIV Nef YY9 epitope, leading to a threonine to serine (T2S) change between days 12 and 20 PI (days 9 and 17 postinfusion) (Table III). This represented an amino acid replacement in the vast majority of the sequenced virus by this time point (<3 wk PI) as detected by the chromatogram from bulk sequencing (Fig. 7). There was an additional point mutation in the Nef YY9 epitope in virus from this monkey between days 38 and 63 PI, with an A to T switch in the codon for the last amino acid of the epitope leading to a tyrosine to phenylalanine switch (Y9F). The latter mutation was observed in circulating virus from the Mamu A*01/A*02-positive animal DBN2 by the same time point, but this animal did not receive T cells targeting this epitope. As expected, no mutation was seen in this epitope in virus from the control Mamu A*02-negative monkey DBK1 (data not shown). No amino acid changes were observed in the SIV Gag CM9 or Vif WY8 epitopes by week 9 PI.

Table III.
Mutations in CD8+ T cell epitope, SIV Nef YY9, following adoptive transfer
Monkey IDPeptide SequenceaSample Dateb% IFN-γ–Producing Cellsc
AZ15 (A*02)d Nef159–167YY9e
YTSGPGIRY (WT)  74 
YSSGPGIRY (T2S variant) 9–17 (12–20) 44 
YSSGPGIRF (T2S; Y9F variant) 35–60 (38–63) 
DBN2 (A*01/*02)d YTSGPGIRF (Y9F variant) 35–60 (38–63) 27 
Monkey IDPeptide SequenceaSample Dateb% IFN-γ–Producing Cellsc
AZ15 (A*02)d Nef159–167YY9e
YTSGPGIRY (WT)  74 
YSSGPGIRY (T2S variant) 9–17 (12–20) 44 
YSSGPGIRF (T2S; Y9F variant) 35–60 (38–63) 
DBN2 (A*01/*02)d YTSGPGIRF (Y9F variant) 35–60 (38–63) 27 
a

WT epitope sequence and observed mutations in virus isolated from acutely infected rhesus macaques; amino acid replacements in variant peptides underlined in boldface.

b

Time frame in days postinfusion (infection) when mutation was observed (i.e., mutation not seen at lower time point in range but seen at higher time point).

c

Frequency of cells positive for IFN-γ in clonal population of CD8+ T cells generated against WT peptide after stimulation with APC pulsed with 2 μg/ml of WT or variant peptide; analyses by ICS and flow cytometry.

d

Monkey MHC class I (Mamu) type of interest.

e

Mamu A*02-restricted epitope.

FIGURE 7.

Escape mutation in the SIV Nef159–167YY9 epitope detected <3 wk PI. Virus isolated from plasma collected from the Mamu A*02-positive monkey AZ15 on days 12 and 20 after challenge with SIVmac239 (days 9 and 17 after T cell infusion) was analyzed by direct sequencing spanning the SIV Nef YY9 epitope. The nucleotide change is highlighted by a black circle with the encoded amino acid indicated.

FIGURE 7.

Escape mutation in the SIV Nef159–167YY9 epitope detected <3 wk PI. Virus isolated from plasma collected from the Mamu A*02-positive monkey AZ15 on days 12 and 20 after challenge with SIVmac239 (days 9 and 17 after T cell infusion) was analyzed by direct sequencing spanning the SIV Nef YY9 epitope. The nucleotide change is highlighted by a black circle with the encoded amino acid indicated.

Close modal

To test if any of the Nef YY9 mutations represented escape from CD8+ T cell recognition, IFN-γ responses by a Nef YY9-specific CD8+ T cell clone was measured by flow cytometry following stimulation with autologous PBMCs pulsed with synthetic wild-type (WT) and variant peptides. All three mutations (T2S alone, T2S and Y9F, and Y9F alone) resulted in diminished or complete loss of recognition of the variant peptide as demonstrated by markedly reduced IFN-γ responses (Table III). Overall, our data showing a rapid escape in the Nef YY9 epitope in plasma virus from the animal AZ15 suggest a role of the infused CD8+ T cells on viral escape.

A number of conditions must be achieved for autologous adoptive T cell transfer to function as a tool for dissecting the role of CD8+ T cells during acute SIV/HIV infection. The first is reliable and consistent means of expansion of cells from a single cell to hundreds of millions, and this must be accomplished while maintaining the specificity and functional phenotype of the T cells. After adoptive transfer, the cells must home to and persist in tissues where viral replication takes place while maintaining their effector function. Targeting a diverse epitope repertoire and preferentially epitopes with a high fitness cost following mutations should help avoid viral escape.

Building on a method for cloning and expansion of human CD8+ T cells that was recently adapted for use in generation of CMV-specific CD8+ T cell clones from M. nemestrina (34, 41), we developed a protocol for isolating and maintaining TCM- and TEM-derived SIV-specific T cell clones from rhesus macaques (35, 39) immunized with a DNA vaccine construct. We were able to maintain CD8+ T cell clones in culture for >5 mo while characterizing them prior to adoptive transfer, thus overcoming one of the main problems hampering large-scale autologous adoptive transfer of CD8+ T cell clones in NHP models of HIV: the inability to keep rhesus macaque-derived SIV-specific CD8+ T cell clones in culture for prolonged periods of time. Berger et al. (34) showed that adoptively transferred TCM-derived CMV-specific T cell clones persist better in PBMCs compared with TEM-derived clones. We could not detect a consistent difference between TCM- and TEM-derived clones in our model, with a TCM-derived clone persisting better in one animal and TEM-derived clones in the other. In a parallel set of experiments infusing autologous virus-specific CD8+ T cells i.p. compared with i.v. to rhesus macaques during chronic SIV infection, we found better persistence of i.p.- compared with i.v.-infused cells in PBMCs (62). However, regardless of the route of infusion (i.p. versus i.v.), and similar to the infusions during acute infection, we observed clonal differences in persistence of the infused cells independent of their origin. This suggests that unknown clonal differences, independent of TCM/TEM origin, played an important role in determining survival in vivo. The difference between the two systems could be due to differences in the disease models, differences between M. nemestrina and M. mulatta, or subtle differences in the protocols used for generating the original clones. For example, whereas we sorted TCM and TEM as CD28+CD95+CCR7+ and CD28CD95+CCR7 CD8+ T cell fractions, respectively, the TCM and TEM populations described in Berger et al. (34) were CD62L+CD28+Fashi and CD62LCD28-Fashi CD8+ T cells, respectively. Furthermore, we did not try to maintain our TCM with IL-15 or IL-7 to improve in vivo survival.

The limited persistence of transferred Ag-specific CD8+ T cell clones in PBMCs compared with bulk uncharacterized CD4+ (52) or CD8+ (53) lymphocytes is possibly related to the extensive in vitro culture of the Ag-specific cells before transfer. Although the infused cells were found to express α4β7 and CD103, markers commonly associated with homing to the gut, no infused cells could be detected in GALT and LN biopsies analyzed on day 2 postinfusion. Similar results were obtained by Bolton et al. (62) in a hemiallogeneic as well as autologous adoptive transfer model in the acute and chronic phase of infection, respectively. This suggests that the transferred T cells had either limited homing to these organs that are important for acute viral replication or, alternatively, that they did home there but were killed, possibly after contact with infected cells. Irrespective of the mechanism involved, the poor or lack of persistence of the infused cells in the GALT in this model may partly explain the lack of an effect on viral replication in the ramp-up phase as well as peak and set point viral load. Strikingly, whereas the infused cells could be detected only for 1 wk in PBMCs and not at all in LNs and GALT, the cells persisted long-term in the lungs (BAL) and were Ag-reactive ex vivo. However, virologic analysis did not show any evidence of antiviral effect in vivo. We detected cell-free SIV RNA as well as cell-associated viral RNA and DNA in BAL in the infused monkeys and the control at levels similar to those reported by others for SIV-infected rhesus macaques (54). Our route of infusion, via the femoral vein, entails initial passage through the pulmonary vasculature before gaining access to the systemic arterial circulation. It is possible that a substantial proportion of the infused cells were trapped in this tissue in a nonspecific manner and thus did not enter the arterial circulation and consequently failed to home to the LNs or GALT. This, together with the data on i.p. versus i.v. infusion by Bolton et al. (62), suggest that different routes of infusion can affect homing and persistence of adoptively transferred cells. In addition, transfection of T cells to induce overexpression of receptors like α4β7 that promote homing to gut mucosa (reviewed in Ref. 55) is currently being evaluated. To improve persistence in vivo, IL-15, which has been shown to provide a stronger survival and proliferation signal to Ag-experienced cells than the low-dose IL-2 used in the current study (34, 50), as well as transduction with genes that enhance cell survival like telomerase (39, 56), could also be evaluated. However, it is important to underscore that the long-term persistence of transferred T cells in the lungs (BAL), together with their preserved capacity to respond to Ag stimulation ex vivo, point to an intrinsic capacity of the infused cells to survive and maintain function in vivo.

When we investigated the effect of the infused CD8+ T cells on the magnitude and kinetics of the endogenous virus-induced T cell responses, a bias could be detected, suggesting a dampening of the total SIV-induced response in animals that received transferred T cells with no detectable effect on the kinetics of the response. However, more infusions will be needed to address whether the observed slight decrease in the magnitude of the endogenous responses is statistically and biologically relevant. Measures of disease progression in the three animals (CD4 counts and viral load) have remained stable and similar between the test and control monkey out to day 200 PI (data not shown).

A key impediment for CD8+ T cell-based vaccines and immunotherapy against HIV/SIV is the high rate of mutations in the virus leading to escape in T cell epitopes (reviewed in Ref. 57). We detected a very early (<3 wk PI) mutation in the Mamu A*02-restricted Nef YY9 epitope (T2S) in plasma virus from AZ15 before the peak in the endogenous virus-specific CD8+ T cell response (36). This early mutation markedly reduced recognition by the cognate CD8+ T cell clones, suggesting that the infused Nef YY9-specific CD8+ T cell clones may have exerted a selective pressure on a replicating virus. DBN2, the other Mamu A*02-positive monkey, which did not receive CD8+ T cells specific for this epitope, did not develop mutations until 5 wk PI. Still, given the limited number of animals in the study, more experiments will be needed to determine the exact role of the transferred cells on the emergence of this escape mutation. Using a more diverse specificity of transferred clones as well as targeting epitopes less likely to mutate due to high fitness cost to the virus would presumably be of benefit.

The route of experimental SIV challenge that presumably reflects the most common mode of natural HIV infection is a limiting dose mucosal challenge, repeated until the animal is infected (58), typified by the involvement of only one or a few variants in establishment of the initial systemic infection (59). It is probable that a limiting-dose mucosal challenge would give adoptively transferred SIV-specific T cells a better chance to impact the infection than the high-dose i.v. challenge used in this study. High-dose i.v. challenge has recently been shown to result in infection by >20 (and possibly several-fold higher) founder viruses (60). It is possible that the transferred T cells were able to significantly reduce the number of founder viruses, but that this did not result in a biologically significant reduction in viral load. This is in agreement with the recent report by Hansen et al. (61) suggesting that persistently activated CD8+ T cells can protect some animals from SIV challenge, but fail to impact the viral load in vaccinated animals that do get infected. Logistically, the repeated low-dose mucosal challenge approach is complex and labor intensive to apply in our model because the billions of expanded T cells cannot be kept ready for infusion in a practical and manageable way. In addition, SIV challenges failing to lead to productive infection may prime cellular or humoral responses, further confounding the interpretation of the experiment. However, an optimized high-dose mucosal (as opposed to repeated low-dose mucosal or high-dose i.v) challenge model that better reflects the most common natural infection could be evaluated in future studies.

In conclusion, this first effort to prevent or significantly diminish the effects of acute SIV infection by adoptive transfer of large numbers of autologous SIV-specific CD8+ T cell clones revealed a number of critical observations: 1) SIV-specific CD8+ T cell clones from rhesus macaques can be generated, characterized, and expanded to numbers sufficient for adoptive transfer; 2) infusion of large numbers of T cells was safe with no adverse reactions detected; 3) the infused cells persisted and remained functional in lungs for an extended period of time (>2 mo), but showed limited persistence and/or homing to gut mucosa and LNs; 4) viral sequence analysis suggested that infusion of SIV-specific CD8+ T cell clones exerted immune pressure on the virus; and finally, 5) CD8+ T cell transfer did not impact the viral peak or set point in a detectable way. Further experiments will address if the lack of impact on virus load is associated with the failure to demonstrate homing/persistence of the cells in gut mucosal tissues and also investigate the impact of transferring clones with more diverse specificities. Alternatively, it is possible that CD8+ T cells exert a limited effect during acute SIV infection and that the presented results reflect that reality. Finally, the described methods for adoptive transfer of macaque T cell clones will also provide an important tool for immunological studies of different NHP infectious disease models.

We thank Fang Yuan, Gary Bowers, Kelli Oswald, and Rebecca Shoemaker for help with the viral load (qPCR) analyses. Vicky Coalter, Adam Wiles, and Rodney Wiles are thanked for help with sample processing. We also thank Dr. Ronald C. Desrosiers for providing the SIVmac239 virus stock and Dr. Brandon Keele for helpful discussions. The following reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH: IL-2 from Hoffman-La Roche, Nutley, NJ; SL8 peptide/MHC tetramer from the NIH Tetramer Facility, Emory University, Atlanta, GA; and SIVmac p27 hybridoma (55-2f12) from Dr. Niels Pedersen.

Disclosures The authors have no financial conflicts of interest.

This work was supported in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract numbers N01-C0-12400 and HHSN261200800001E.

The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

The online version of this article contains supplemental material.

Abbreviations used in this paper:

BAL

bronchoalveolar lavage

ICS

intracellular cytokine staining

LN

lymph node

NHP

nonhuman primate

NIH

National Institutes of Health

PI

postinfection

qPCR

quantitative PCR

T2S

threonine to serine

TCM

central memory T cell

TEM

effector memory T cell

TM B-LCL

human EBV-transformed B cell line

WT

wild-type

Y9F

tyrosine to phenylalanine.

1
Hofmann-Lehmann
R.
,
Vlasak
J.
,
Rasmussen
R. A.
,
Smith
B. A.
,
Baba
T. W.
,
Liska
V.
,
Ferrantelli
F.
,
Montefiori
D. C.
,
McClure
H. M.
,
Anderson
D. C.
, et al
.
2001
.
Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.
J. Virol.
75
:
7470
7480
.
2
Mascola
J. R.
,
Lewis
M. G.
,
Stiegler
G.
,
Harris
D.
,
VanCott
T. C.
,
Hayes
D.
,
Louder
M. K.
,
Brown
C. R.
,
Sapan
C. V.
,
Frankel
S. S.
, et al
.
1999
.
Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.
J. Virol.
73
:
4009
4018
.
3
Veazey
R. S.
,
Shattock
R. J.
,
Pope
M.
,
Kirijan
J. C.
,
Jones
J.
,
Hu
Q.
,
Ketas
T.
,
Marx
P. A.
,
Klasse
P. J.
,
Burton
D. R.
,
Moore
J. P.
.
2003
.
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.
Nat. Med.
9
:
343
346
.
4
Shiver
J. W.
,
Fu
T. M.
,
Chen
L.
,
Casimiro
D. R.
,
Davies
M. E.
,
Evans
R. K.
,
Zhang
Z. Q.
,
Simon
A. J.
,
Trigona
W. L.
,
Dubey
S. A.
, et al
.
2002
.
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
Nature
415
:
331
335
.
5
Rose
N. F.
,
Marx
P. A.
,
Luckay
A.
,
Nixon
D. F.
,
Moretto
W. J.
,
Donahoe
S. M.
,
Montefiori
D.
,
Roberts
A.
,
Buonocore
L.
,
Rose
J. K.
.
2001
.
An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.
Cell
106
:
539
549
.
6
Belyakov
I. M.
,
Hel
Z.
,
Kelsall
B.
,
Kuznetsov
V. A.
,
Ahlers
J. D.
,
Nacsa
J.
,
Watkins
D. I.
,
Allen
T. M.
,
Sette
A.
,
Altman
J.
, et al
.
2001
.
Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques.
Nat. Med.
7
:
1320
1326
.
7
Barouch
D. H.
,
Santra
S.
,
Schmitz
J. E.
,
Kuroda
M. J.
,
Fu
T. M.
,
Wagner
W.
,
Bilska
M.
,
Craiu
A.
,
Zheng
X. X.
,
Krivulka
G. R.
, et al
.
2000
.
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.
Science
290
:
486
492
.
8
Hel
Z.
,
Nacsa
J.
,
Tryniszewska
E.
,
Tsai
W. P.
,
Parks
R. W.
,
Montefiori
D. C.
,
Felber
B. K.
,
Tartaglia
J.
,
Pavlakis
G. N.
,
Franchini
G.
.
2002
.
Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses.
J. Immunol.
169
:
4778
4787
.
9
Hazuda
D. J.
,
Young
S. D.
,
Guare
J. P.
,
Anthony
N. J.
,
Gomez
R. P.
,
Wai
J. S.
,
Vacca
J. P.
,
Handt
L.
,
Motzel
S. L.
,
Klein
H. J.
, et al
.
2004
.
Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques.
Science
305
:
528
532
.
10
Fernandez
C. S.
,
Smith
M. Z.
,
Batten
C. J.
,
De Rose
R.
,
Reece
J. C.
,
Rollman
E.
,
Venturi
V.
,
Davenport
M. P.
,
Kent
S. J.
.
2007
.
Vaccine-induced T cells control reversion of AIDS virus immune escape mutants.
J. Virol.
81
:
4137
4144
.
11
Barouch
D. H.
,
Kunstman
J.
,
Kuroda
M. J.
,
Schmitz
J. E.
,
Santra
S.
,
Peyerl
F. W.
,
Krivulka
G. R.
,
Beaudry
K.
,
Lifton
M. A.
,
Gorgone
D. A.
, et al
.
2002
.
Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.
Nature
415
:
335
339
.
12
Ueno
T.
,
Idegami
Y.
,
Motozono
C.
,
Oka
S.
,
Takiguchi
M.
.
2007
.
Altering effects of antigenic variations in HIV-1 on antiviral effectiveness of HIV-specific CTLs.
J. Immunol.
178
:
5513
5523
.
13
Loffredo
J. T.
,
Burwitz
B. J.
,
Rakasz
E. G.
,
Spencer
S. P.
,
Stephany
J. J.
,
Vela
J. P.
,
Martin
S. R.
,
Reed
J.
,
Piaskowski
S. M.
,
Furlott
J.
, et al
.
2007
.
The antiviral efficacy of simian immunodeficiency virus-specific CD8+ T cells is unrelated to epitope specificity and is abrogated by viral escape.
J. Virol.
81
:
2624
2634
.
14
Loffredo
J. T.
,
Sidney
J.
,
Wojewoda
C.
,
Dodds
E.
,
Reynolds
M. R.
,
Napoé
G.
,
Mothé
B. R.
,
O’Connor
D. H.
,
Wilson
N. A.
,
Watkins
D. I.
,
Sette
A.
.
2004
.
Identification of seventeen new simian immunodeficiency virus-derived CD8+ T cell epitopes restricted by the high frequency molecule, Mamu-A*02, and potential escape from CTL recognition.
J. Immunol.
173
:
5064
5076
.
15
Jin
X.
,
Bauer
D. E.
,
Tuttleton
S. E.
,
Lewin
S.
,
Gettie
A.
,
Blanchard
J.
,
Irwin
C. E.
,
Safrit
J. T.
,
Mittler
J.
,
Weinberger
L.
, et al
.
1999
.
Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.
J. Exp. Med.
189
:
991
998
.
16
Metzner
K. J.
,
Jin
X.
,
Lee
F. V.
,
Gettie
A.
,
Bauer
D. E.
,
Di Mascio
M.
,
Perelson
A. S.
,
Marx
P. A.
,
Ho
D. D.
,
Kostrikis
L. G.
,
Connor
R. I.
.
2000
.
Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine.
J. Exp. Med.
191
:
1921
1931
.
17
Lifson
J. D.
,
Rossio
J. L.
,
Piatak
M.
 Jr
,
Parks
T.
,
Li
L.
,
Kiser
R.
,
Coalter
V.
,
Fisher
B.
,
Flynn
B. M.
,
Czajak
S.
, et al
.
2001
.
Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment.
J. Virol.
75
:
10187
10199
.
18
Ellenberger
D.
,
Otten
R. A.
,
Li
B.
,
Aidoo
M.
,
Rodriguez
I. V.
,
Sariol
C. A.
,
Martinez
M.
,
Monsour
M.
,
Wyatt
L.
,
Hudgens
M. G.
, et al
.
2006
.
HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges.
Virology
352
:
216
225
.
19
Barouch
D. H.
,
Santra
S.
,
Kuroda
M. J.
,
Schmitz
J. E.
,
Plishka
R.
,
Buckler-White
A.
,
Gaitan
A. E.
,
Zin
R.
,
Nam
J. H.
,
Wyatt
L. S.
, et al
.
2001
.
Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination.
J. Virol.
75
:
5151
5158
.
20
Amara
R. R.
,
Villinger
F.
,
Altman
J. D.
,
Lydy
S. L.
,
O’Neil
S. P.
,
Staprans
S. I.
,
Montefiori
D. C.
,
Xu
Y.
,
Herndon
J. G.
,
Wyatt
L. S.
, et al
.
2001
.
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.
Science
292
:
69
74
.
21
Cafaro
A.
,
Caputo
A.
,
Fracasso
C.
,
Maggiorella
M. T.
,
Goletti
D.
,
Baroncelli
S.
,
Pace
M.
,
Sernicola
L.
,
Koanga-Mogtomo
M. L.
,
Betti
M.
, et al
.
1999
.
Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine.
Nat. Med.
5
:
643
650
.
22
Pantaleo
G.
,
Koup
R. A.
.
2004
.
Correlates of immune protection in HIV-1 infection: what we know, what we don’t know, what we should know.
Nat. Med.
10
:
806
810
.
23
Sekaly
R. P.
2008
.
The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?
J. Exp. Med.
205
:
7
12
.
24
Greenberg
P. D.
.
1991
.
Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells.
Adv. Immunol.
49
:
281
355
.
25
Pahl-Seibert
M. F.
,
Juelch
M.
,
Podlech
J.
,
Thomas
D.
,
Deegen
P.
,
Reddehase
M. J.
,
Holtappels
R.
.
2005
.
Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting.
J. Virol.
79
:
5400
5413
.
26
Hasenkrug
K. J.
,
Dittmer
U.
.
2007
.
Immune control and prevention of chronic Friend retrovirus infection.
Front. Biosci.
12
:
1544
1551
.
27
Rooney
C. M.
,
Smith
C. A.
,
Ng
C. Y.
,
Loftin
S. K.
,
Sixbey
J. W.
,
Gan
Y.
,
Srivastava
D. K.
,
Bowman
L. C.
,
Krance
R. A.
,
Brenner
M. K.
,
Heslop
H. E.
.
1998
.
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.
Blood
92
:
1549
1555
.
28
Dudley
M. E.
,
Wunderlich
J. R.
,
Robbins
P. F.
,
Yang
J. C.
,
Hwu
P.
,
Schwartzentruber
D. J.
,
Topalian
S. L.
,
Sherry
R.
,
Restifo
N. P.
,
Hubicki
A. M.
, et al
.
2002
.
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
Science
298
:
850
854
.
29
Bollard
C. M.
,
Aguilar
L.
,
Straathof
K. C.
,
Gahn
B.
,
Huls
M. H.
,
Rousseau
A.
,
Sixbey
J.
,
Gresik
M. V.
,
Carrum
G.
,
Hudson
M.
, et al
.
2004
.
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin’s disease.
J. Exp. Med.
200
:
1623
1633
.
30
Dudley
M. E.
,
Wunderlich
J. R.
,
Yang
J. C.
,
Sherry
R. M.
,
Topalian
S. L.
,
Restifo
N. P.
,
Royal
R. E.
,
Kammula
U.
,
White
D. E.
,
Mavroukakis
S. A.
, et al
.
2005
.
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
J. Clin. Oncol.
23
:
2346
2357
.
31
Walter
E. A.
,
Greenberg
P. D.
,
Gilbert
M. J.
,
Finch
R. J.
,
Watanabe
K. S.
,
Thomas
E. D.
,
Riddell
S. R.
.
1995
.
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.
N. Engl. J. Med.
333
:
1038
1044
.
32
Koff
W. C.
,
Johnson
P. R.
,
Watkins
D. I.
,
Burton
D. R.
,
Lifson
J. D.
,
Hasenkrug
K. J.
,
McDermott
A. B.
,
Schultz
A.
,
Zamb
T. J.
,
Boyle
R.
,
Desrosiers
R. C.
.
2006
.
HIV vaccine design: insights from live attenuated SIV vaccines.
Nat. Immunol.
7
:
19
23
.
33
Johnson
R. P.
.
2002
.
Mechanisms of protection against simian immunodeficiency virus infection.
Vaccine
20
:
1985
1987
.
34
Berger
C.
,
Jensen
M. C.
,
Lansdorp
P. M.
,
Gough
M.
,
Elliott
C.
,
Riddell
S. R.
.
2008
.
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.
J. Clin. Invest.
118
:
294
305
.
35
Minang
J. T.
,
Barsov
E. V.
,
Yuan
F.
,
Trivett
M. T.
,
Piatak
M.
 Jr
,
Lifson
J. D.
,
Ott
D. E.
,
Ohlen
C.
.
2008
.
Efficient inhibition of SIV replication in rhesus CD4+ T-cell clones by autologous immortalized SIV-specific CD8+ T-cell clones.
Virology
372
:
430
441
.
36
Allen
T. M.
,
O’Connor
D. H.
,
Jing
P.
,
Dzuris
J. L.
,
Mothé
B. R.
,
Vogel
T. U.
,
Dunphy
E.
,
Liebl
M. E.
,
Emerson
C.
,
Wilson
N.
, et al
.
2000
.
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.
Nature
407
:
386
390
.
37
Reynolds
M. R.
,
Rakasz
E.
,
Skinner
P. J.
,
White
C.
,
Abel
K.
,
Ma
Z. M.
,
Compton
L.
,
Napoé
G.
,
Wilson
N.
,
Miller
C. J.
, et al
.
2005
.
CD8+ T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: too late and too little.
J. Virol.
79
:
9228
9235
.
38
Rosati
M.
,
Valentin
A.
,
Jalah
R.
,
Patel
V.
,
von Gegerfelt
A.
,
Bergamaschi
C.
,
Alicea
C.
,
Weiss
D.
,
Treece
J.
,
Pal
R.
, et al
.
2008
.
Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation.
Vaccine
26
:
5223
5229
.
39
Andersen
H.
,
Barsov
E. V.
,
Trivett
M. T.
,
Trubey
C. M.
,
Giavedoni
L. D.
,
Lifson
J. D.
,
Ott
D. E.
,
Ohlén
C.
.
2007
.
Transduction with human telomerase reverse transcriptase immortalizes a rhesus macaque CD8+ T cell clone with maintenance of surface marker phenotype and function.
AIDS Res. Hum. Retroviruses
23
:
456
465
.
40
O’Connor
D. H.
,
Mothe
B. R.
,
Weinfurter
J. T.
,
Fuenger
S.
,
Rehrauer
W. M.
,
Jing
P.
,
Rudersdorf
R. R.
,
Liebl
M. E.
,
Krebs
K.
,
Vasquez
J.
, et al
.
2003
.
Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses.
J. Virol.
77
:
9029
9040
.
41
Riddell
S. R.
,
Greenberg
P. D.
.
1990
.
The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells.
J. Immunol. Methods
128
:
189
201
.
42
Berger
C.
,
Huang
M. L.
,
Gough
M.
,
Greenberg
P. D.
,
Riddell
S. R.
,
Kiem
H. P.
.
2001
.
Nonmyeloablative immunosuppressive regimen prolongs In vivo persistence of gene-modified autologous T cells in a nonhuman primate model.
J. Virol.
75
:
799
808
.
43
Frahm
N.
,
Korber
B. T.
,
Adams
C. M.
,
Szinger
J. J.
,
Draenert
R.
,
Addo
M. M.
,
Feeney
M. E.
,
Yusim
K.
,
Sango
K.
,
Brown
N. V.
, et al
.
2004
.
Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities.
J. Virol.
78
:
2187
2200
.
44
Robinson
S.
,
Charini
W. A.
,
Newberg
M. H.
,
Kuroda
M. J.
,
Lord
C. I.
,
Letvin
N. L.
.
2001
.
A commonly recognized simian immunodeficiency virus Nef epitope presented to cytotoxic T lymphocytes of Indian-origin rhesus monkeys by the prevalent major histocompatibility complex class I allele Mamu-A*02.
J. Virol.
75
:
10179
10186
.
45
O’Connor
D. H.
,
Allen
T. M.
,
Vogel
T. U.
,
Jing
P.
,
DeSouza
I. P.
,
Dodds
E.
,
Dunphy
E. J.
,
Melsaether
C.
,
Mothé
B.
,
Yamamoto
H.
, et al
.
2002
.
Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection.
Nat. Med.
8
:
493
499
.
46
Minang
J. T.
,
Trivett
M. T.
,
Coren
L. V.
,
Barsov
E. V.
,
Piatak
M.
 Jr
,
Chertov
O.
,
Chertova
E.
,
Ott
D. E.
,
Ohlen
C.
.
2008
.
The Mamu B 17-restricted SIV Nef IW9 to TW9 mutation abrogates correct epitope processing and presentation without loss of replicative fitness.
Virology
375
:
307
314
.
47
Cline
A. N.
,
Bess
J. W.
,
Piatak
M.
 Jr
,
Lifson
J. D.
.
2005
.
Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS.
J. Med. Primatol.
34
:
303
312
.
48
Mummidi
S.
,
Bamshad
M.
,
Ahuja
S. S.
,
Gonzalez
E.
,
Feuillet
P. M.
,
Begum
K.
,
Galvis
M. C.
,
Kostecki
V.
,
Valente
A. J.
,
Murthy
K. K.
, et al
.
2000
.
Evolution of human and non-human primate CC chemokine receptor 5 gene and mRNA. Potential roles for haplotype and mRNA diversity, differential haplotype-specific transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the pathogenesis of HIV-1 and simian immunodeficiency virus.
J. Biol. Chem.
275
:
18946
18961
.
49
Kestler
H.
,
Kodama
T.
,
Ringler
D.
,
Marthas
M.
,
Pedersen
N.
,
Lackner
A.
,
Regier
D.
,
Sehgal
P.
,
Daniel
M.
,
King
N.
, et al
.
1990
.
Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus.
Science
248
:
1109
1112
.
50
Picker
L. J.
,
Reed-Inderbitzin
E. F.
,
Hagen
S. I.
,
Edgar
J. B.
,
Hansen
S. G.
,
Legasse
A.
,
Planer
S.
,
Piatak
M.
 Jr
,
Lifson
J. D.
,
Maino
V. C.
, et al
.
2006
.
IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates.
J. Clin. Invest.
116
:
1514
1524
.
51
Brenchley
J. M.
,
Paiardini
M.
,
Knox
K. S.
,
Asher
A. I.
,
Cervasi
B.
,
Asher
T. E.
,
Scheinberg
P.
,
Price
D. A.
,
Hage
C. A.
,
Kholi
L. M.
, et al
.
2008
.
Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections.
Blood
112
:
2826
2835
.
52
Villinger
F.
,
Brice
G. T.
,
Mayne
A. E.
,
Bostik
P.
,
Mori
K.
,
June
C. H.
,
Ansari
A. A.
.
2002
.
Adoptive transfer of simian immunodeficiency virus (SIV) naïve autologous CD4(+) cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status.
Blood
99
:
590
599
.
53
Greene
J. M.
,
Burwitz
B. J.
,
Blasky
A. J.
,
Mattila
T. L.
,
Hong
J. J.
,
Rakasz
E. G.
,
Wiseman
R. W.
,
Hasenkrug
K. J.
,
Skinner
P. J.
,
O’Connor
S. L.
,
O’Connor
D. H.
.
2008
.
Allogeneic lymphocytes persist and traffic in feral MHC-matched mauritian cynomolgus macaques.
PLoS ONE
3
:
e2384
.
54
Barber
S. A.
,
Gama
L.
,
Li
M.
,
Voelker
T.
,
Anderson
J. E.
,
Zink
M. C.
,
Tarwater
P. M.
,
Carruth
L. M.
,
Clements
J. E.
.
2006
.
Longitudinal analysis of simian immunodeficiency virus (SIV) replication in the lungs: compartmentalized regulation of SIV.
J. Infect. Dis.
194
:
931
938
.
55
Agace
W. W.
2006
.
Tissue-tropic effector T cells: generation and targeting opportunities.
Nat. Rev. Immunol.
6
:
682
692
.
56
Zhou
J.
,
Dudley
M. E.
,
Rosenberg
S. A.
,
Robbins
P. F.
.
2004
.
Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma.
J. Immunol.
173
:
7622
7629
.
57
Walker
B. D.
,
Burton
D. R.
.
2008
.
Toward an AIDS vaccine.
Science
320
:
760
764
.
58
Wilson
N. A.
,
Reed
J.
,
Napoe
G. S.
,
Piaskowski
S.
,
Szymanski
A.
,
Furlott
J.
,
Gonzalez
E. J.
,
Yant
L. J.
,
Maness
N. J.
,
May
G. E.
, et al
.
2006
.
Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239.
J. Virol.
80
:
5875
5885
.
59
Keele
B. F.
,
Giorgi
E. E.
,
Salazar-Gonzalez
J. F.
,
Decker
J. M.
,
Pham
K. T.
,
Salazar
M. G.
,
Sun
C.
,
Grayson
T.
,
Wang
S.
,
Li
H.
, et al
.
2008
.
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.
Proc. Natl. Acad. Sci. USA
105
:
7552
7557
.
60
Keele
B. F.
,
Li
H.
,
Learn
G. H.
,
Hraber
P.
,
Giorgi
E. E.
,
Grayson
T.
,
Sun
C.
,
Chen
Y.
,
Yeh
W. W.
,
Letvin
N. L.
, et al
.
2009
.
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1.
J. Exp. Med.
206
:
1117
1134
.
61
Hansen
S. G.
,
Vieville
C.
,
Whizin
N.
,
Coyne-Johnson
L.
,
Siess
D. C.
,
Drummond
D. D.
,
Legasse
A. W.
,
Axthelm
M. K.
,
Oswald
K.
,
Trubey
C. M.
, et al
.
2009
.
Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge.
Nat. Med.
15
:
293
299
.
62
Bolton
D. L.
,
Minang
J. T.
,
Trivett
M. T.
,
Song
K.
,
Tuscher
J. J.
,
Li
Y.
,
Piatak
M.
 Jr
,
O'Connor
D.
,
Lifson
J. D.
,
Roederer
M.
, et al
.
2010
.
Trafficking, persistence, and activation state of adoptively transferred allogeneic and autologous simian immunodeficiency virus-specific CD8+ T cell clones during acute and chronic infection of rhesus macaques.
J. Immunol
.
184
:
303
314
.
63
Rosati
M.
,
Bergamaschi
C.
,
Valentin
A.
,
Kulkarni
V.
,
Jalah
R.
,
Alicea
C.
,
patel
V.
,
von Gegerfelt
A. S.
,
Montefiori
D. C.
,
Venzon
D. J.
, et al
.
2009
.
DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge.
Proc. Natl. Acad. Sci. USA
106
:
15831
15836
.